ZFIN Image: Yan et al., 2021, Figure 7.

Image

Figure Caption

Figure 7.

EGFR-specific T cell immunotherapies for the treatment of RMS. (A–D) rag2^Δ/Δ, il2rga^−/− animals engrafted by IP injection with EGFP⁺ RD cells and then coadministered weekly (i) control EGFR antibody along with CD8⁺ T cells, (ii) EGFR CAR T cells, (iii) EGFR/CD3 BiTE with CD8⁺ T cells, or (iv) EGFR-M14C with CMV-specific CD8⁺ T cells. Relative growth assessed by whole animal imaging with dosing noted by arrowheads (A). Quantification of proliferation by Ki67 IHC (B), cellularity based on H&E staining (C), and cell apoptosis by TUNEL (D) at 28 dpt. n = 3 animals/condition (B–D). (E–I) 3D modeling of T cell immunotherapy responses in animals engrafted with mCherry⁺/ZipGFP-Casp3⁺ RD cells into the periocular muscle imaged at 11 dpt. Control treated T cells (left, E) and T cell immunotherapy (right panels, E). Arrows denote representative examples of apoptotic tumor cells. Quantitation of therapy effects on tumor cell number (F; growth), tumor cell apoptosis (G), T cells infiltrated into tumor mass (H), and percentage of T cells in contact with apoptotic tumor cells (I). n = 5 animals/condition (A and F–I). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001, Student’s t test. Scale bar equals 10 µm (E). Error bars denote ±SD (A–D and F–I).

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J. Exp. Med.